# Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks

> **NCT00700622** · PHASE3 · TERMINATED · sponsor: **Mannkind Corporation** · enrollment: 130 (actual)

## Conditions studied

- Diabetes, Type 1

## Interventions

- **DRUG:** Technosphere Insulin
- **DRUG:** Insulin glargine
- **DRUG:** Insulin lispro

## Key facts

- **NCT ID:** NCT00700622
- **Lead sponsor:** Mannkind Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2009-11
- **Final completion:** 2010-03
- **Target enrollment:** 130 (ACTUAL)
- **Why stopped:** Sponsor stopped development of the MedTone inhaler in favor of an improved device (Gen2 inhaler)
- **Last updated:** 2014-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00700622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00700622, "Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00700622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*